Vitruvian is changing the standard of care for abdominal surgery. There are 5 million open abdominal operations performed each year in the United States. Approximately 15% subsequently develop an incisional hernia resulting in over 400,000 incisional hernia repairs each year. The industry and providers are primarily focused on improved repair materials and surgical techniques, instead of the optimal solution: prevention. Vitruvian has developed MYOSEAL, a proprietary fibrin tissue sealant enhanced with bioactive microparticle technology that increases wound healing. Compelling preclinical data have demonstrated that MYOSEAL prevents incisional hernias through enhanced wound healing.
Vitruvian is currently seeking $850K in seed financing to develop and certify the regulatory strategy, source and manufacture the product, conduct GLP-quality toxicology and biocompatibility studies, design the First-in-Man clinical trial and file additional IP.